Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis

[Display omitted] •Bumpked kinase inhibitor (BKI) 1369 selectively targets Cryptosporidium parvum calcium-dependent protein kinase 1.•It is more potent than nitazoxanide against Cryptosporidium hominis and three strains of C. parvum.•Two identified metabolites have no cytotoxicity against mammalian...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal for parasitology 2017-10, Vol.47 (12), p.753-763
Hauptverfasser:	Hulverson, Matthew A., Choi, Ryan, Arnold, Samuel L.M., Schaefer, Deborah A., Hemphill, Andrew, McCloskey, Molly C., Betzer, Dana P., Müller, Joachim, Vidadala, Rama S.R., Whitman, Grant R., Rivas, Kasey L., Barrett, Lynn K., Hackman, Robert C., Love, Melissa S., McNamara, Case W., Shaughnessy, Thomas K., Kondratiuk, Alison, Kurnick, Matthew, Banfor, Patricia N., Lynch, James J., Freiberg, Gail M., Kempf, Dale J., Maly, Dustin J., Riggs, Michael W., Ojo, Kayode K., Van Voorhis, Wesley C.
Format:	Artikel
Sprache:	eng
Schlagworte:	BKI 1369 Calcium-dependent protein kinase 1 calves Cryptosporidiosis Drug target Gatekeeper residue humans mice neonates pharmacodynamics therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!